ETF·NYSE
State Street Health Care Select Sector SPDR ETF (XLV)
- Net assets
- $43.39B
- Expense ratio
- 0.08%
- Yield
- 1.52%
- 52-week range
- $141.39 $178.86
The short version
Where XLV stands today, in four lines, and what CleaRank Financial AI makes of it.
XLV at a glance
State Street Health Care Select Sector SPDR ETF (XLV): Buy, 75/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($169.75 and $157.41).
- Fund Expense ratio 0.08%, $43.4B in net assets, +22.9% total return over 1 year.
Figures as of October 16, 2026.
CleaRank Financial AI
The State Street Health Care Select Sector SPDR ETF (XLV) is currently trading at $177.19, showing a strong upward trend.
The ETF is positioned above its 20-day EMA ($170.28), 50-day SMA ($169.75), and 200-day SMA ($157.41), signaling positive momentum. Its Year-to-Date return stands at 10.08%, reflecting the sector's performance in the current market environment. The fund's strategy focuses on providing broad exposure to U.S. health care companies across various sub-sectors, including pharmaceuticals, biotechnology, and health care services.
Only on CleaRank
Figures we compute ourselves from XLV's own price history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $177.19 is 4.4% above the 50-day simple moving average of $169.75.Price above its 200-day average ›
The price is 12.6% above the 200-day simple moving average of $157.41.50-day average above the 200-day ›
The 50-day average ($169.75) is 7.8% above the 200-day average ($157.41), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 96% of its 52-week range, between $141.39 and $178.86.
XLV share price
Pick a period: each tab shows how far XLV has moved over it, to the last close.
Today's trading
Where XLV sits inside today's range and its 52-week range.
Fund facts and valuation
What the fund holds, what it costs and how it is valued.
Fund checks
4/5Expense ratio at or below 0.20% ›
The fund charges 0.08% a year, $8.00 on a $10,000 holding.Over $1B in net assets ›
Net assets total $43.4B.No sector above 35% of the fund ›
The largest sector, Healthcare, makes up 100.0% of the fund.Pays a distribution ›
The distribution yield is 1.52%.Positive return over one year ›
The fund family reports a one-year total return of 22.90%.
XLV Fund Facts
State Street Health Care Select Sector SPDR ETF is a sector-focused exchange-traded fund that provides broad exposure to U.S. health care companies. The fund is designed to track the Health Care Select Sector Index, giving investors access to a diversified mix of large-cap businesses across pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, life sciences tools and services, and health care technology.
Sector weights
Trailing total returns
| Period | XLV |
|---|---|
| YTD | 10.08% |
| 1 month | -0.90% |
| 3 months | 6.44% |
| 1 year | 22.90% |
| 3 years | 11.18% |
| 5 years | 7.48% |
| 10 years | 10.69% |
As of Oct 16, 2026, XLV has an expense ratio of 0.08%, $43.39B in net assets and a distribution yield of 1.52%.
Fund reference data as of Oct 16, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change.
Key statistics
The headline figures for XLV.
What the numbers say
CleaRank Financial AI's reading of XLV's holdings, performance and risks.
The State Street Health Care Select Sector SPDR ETF (XLV) holds 100.00% in Healthcare stocks, offering concentrated exposure to this vital sector.
The fund's strategy, managed by State Street Investment Management, aims to mirror the Health Care Select Sector Index, providing a diversified mix of large-cap U.S. health care companies. This includes businesses involved in pharmaceuticals, biotechnology, health care equipment, and services. The sector's performance is a key driver for the ETF's returns, and its broad exposure makes it a significant tool for investors seeking targeted healthcare sector allocation within the S&P 500.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 67.5, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 67.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of XLV
The score, the reasoning behind it, and what could move the price next.
Technical indicators
Momentum and trend for XLV, from its daily closes.
As of October 16, 2026, with XLV at $177.19, its 14-day RSI is 67.5 (showing bullish momentum without being overbought), its 50-day simple moving average is $169.75 and its 200-day is $157.41.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What XLV moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, XLV's 1-year correlation of daily returns is +0.43 with S&P 500 (SPY), +0.24 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.10 with gold (XAU).
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
XLV trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from XLV's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much XLV tends to move, against the market and on its own.
The long record
XLV's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.05% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 21.5%, from January 2020 to March 2020, regained by July 2020.Most 1-year holds ended higher ›
86% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $30,165, against $42,525 in the S&P 500 (SPY).
XLV Drawdowns & Recovery
As of October 16, 2026, XLV's worst peak-to-trough fall over the last 10 years with dividends reinvested was -21.5% (January 2020 to March 2020); it regained that peak by July 2020, 4 months after the low, and 86% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into XLV in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: XLV trailed the S&P 500 over this period: $30,165 against $42,525.
A $10,000 investment in XLV in October 2016 would be worth about $30,165 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to XLV, and which have not.
Strongest month, November: an average of +3.57%, up in 8 of 10 years.
Weakest month, March: an average of -1.58%, up in 3 of 10 years.
This month, October: has averaged +0.56%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, XLV's strongest calendar month has been November (average +3.57%, up in 8 of 10 years) and its weakest March (average -1.58%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in XLV, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in XLV today could grow to about $20,977 by 2036 in the base case, with a 90th-percentile outcome near $41,437 and a 10th-percentile outcome around $10,619 (above the amount invested: over ten years most simulated paths of a rising, moderately volatile asset end higher). The simulation models price only; at today's 1.52% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
XLV 2030 Scenarios (Monte Carlo)
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $238 for XLV by 2030 in the base case, from $177 today (1.3x over 4 years). The 10th-percentile path ends near $155. These are outcomes of a Monte Carlo simulation run on XLV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $154 | $191 | $237 | |
| 2028 | $152 | $205 | $279 | |
| 2029 | $152 | $221 | $321 | |
| 2030 | $155 | $238 | $367 | |
| 2031 | $159 | $257 | $415 |
Method: a lognormal simulation of XLV's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Questions people ask
Answered from the figures on this page, as of October 16, 2026.